Dupilumab Efficacy and Safety as an Add-On Therapy in Uncontrolled Asthma Patients: A Systematic Review
Article Sidebar
Main Article Content
Abstract
Asthma is a heterogeneous chronic inflammatory condition affecting the lung. Standard treatment, a high-dose inhaled corticosteroid (ICS) and long-acting bronchodilator (LABA), effectively manages asthma in most individuals. However, 5%-10% of individuals with asthma were ineffective with those treatments. Recent RCTs suggested that Dupilumab posed potential as an add-on therapy. This systematic review aims to support the efficacy (the annualized rate of severe asthma exacerbation and increase in FEV1) and the safety of Dupilumab as an add-on therapy in uncontrolled asthma patients. We used "(Asthma) AND (Dupilumab)" as keywords on PubMed and ScienceDirect. We included only RCT design studies comparing the efficacy and safety of Dupilumab with a placebo in uncontrolled asthma patients. The placebo was ICS and LABA or oral glucocorticoids. This paper included five RCTs with 3400 participants, and their quality was assessed using Critical Appraisal Tools Program (CASP) tools. We conducted a meta-analysis to calculate the pooled risk ratio (RR). In addition, we used Mantel-Haenszel with 95% confidence intervals for dichotomous data. Furthermore, we used a random-effects model to count for interstudy heterogeneity. Then, we processed data using Revman 5.4. Dupilumab as an add-on therapy significantly showed a consistent effect in lower the annualized rate of severe asthma exacerbation (RR= 0.46; 95% CI 0.36- 0.58; p=0.007) and increased FEV1 compared to placebo. In addition, the most common adverse effect of using Dupilumab were injection site reaction, upper respiratory tract infections, and eosinophilia. In conclusion, Dupilumab is safe and well-tolerated as moderate-to-severe uncontrolled asthma add-on therapy
Downloads
Article Details
Copyright (c) 2022 Evelyn Evelyn, Putra, Fauna Herawati
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Bacharier, L.B. et al. (2021) 'Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.', The New England journal of medicine, 385(24), pp. 2230–2240. doi:10.1056/NEJMoa2106567. DOI: https://doi.org/10.1056/NEJMoa2106567
CASP (2020) Critical Appraisal Skills Programme (Randomised Controlled Trial) Checklist. doi:10.1371/journal.pone.0118134. DOI: https://doi.org/10.1371/journal.pone.0118134
Castro, M. et al. (2018) 'Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.', The New England journal of medicine, 378(26), pp. 2486–2496. doi:10.1056/NEJMoa1804092. DOI: https://doi.org/10.1056/NEJMoa1804092
Farne, HA et al. (2017) 'Anti-IL5 therapies for asthma', Cochrane Database of Systematic Reviews, 2017(9). doi:10.1002/14651858.CD010834.pub3. DOI: https://doi.org/10.1002/14651858.CD010834.pub3
FDA (2017a) FDA approves new eczema drug Dupixent. doi:10.31525/cmr-29dd256. DOI: https://doi.org/10.31525/cmr-29dd256
FDA (2017b) 'Xolair (omalizumab) for injection, for subcutaneous use', The United States Package Insert (USPI) Revised Jun 2017 [Preprint].
GINA, AGI for (2021) 'Global Strategy for Asthma Management and Prevention'.
Global Asthma Network (2018) The Global Asthma Report. Global Asthma Network.
Harb, H. and Chatila, T. (2017) 'Mechanisms of Dupilumab Hani', Physiology & behavior, 176(10), pp. 139–148. doi:10.1111/cea.13491.Mechanisms.
Harb, H. and Chatila, TA (2020) 'Mechanisms of Dupilumab', Clinical and Experimental Allergy, 50(1), pp. 5–14. doi:10.1111/cea.13491. DOI: https://doi.org/10.1111/cea.13491
Kemenkes RI (2019) ‘Hasil Riset Kesehatan Dasar Tahun 2018’, Kementrian Kesehatan RI, 53(9), pp. 1689–1699.
Page, M.J. et al. (2021) 'The PRISMA 2020 statement: An updated guideline for reporting systematic DOI: https://doi.org/10.31222/osf.io/v7gm2
https://doi.org/10.33086/jhs.v15i03.2788 Evelyn - Dupilumab Efficacy and Safety as an Add-On Therapy in Uncontrolled
Asthma Patients: A Systematic Review
reviews', The BMJ, 372, pp. 2020–2021. doi:10.1136/bmj.n71. DOI: https://doi.org/10.1136/bmj.n71
Papi, A. et al. (2018) 'Asthma', The Lancet, 391(10122), pp. 783–800. doi:10.1016/S0140-6736(17)33311-1. DOI: https://doi.org/10.1016/S0140-6736(17)33311-1
Rabe, K.F. et al. (2018) 'Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.', The New England journal of medicine, 378(26), pp. 2475–2485. doi:10.1056/NEJMoa1804093. DOI: https://doi.org/10.1056/NEJMoa1804093
Ricciardolo, F.L.M., Bertolini, F. and Carriero, V. (2021) ‘The role of dupilumab in severe asthma’, Biomedicines, 9(9). doi:10.3390/biomedicines9091096. DOI: https://doi.org/10.3390/biomedicines9091096
Rogliani, P. et al. (2020) 'Severe Asthma and Biological Therapy: When, Which, and for Whom', Pulmonary Therapy, 6(1), pp. 47–66. doi:10.1007/s41030-019-00109-1. DOI: https://doi.org/10.1007/s41030-019-00109-1
Rothe, T. et al. (2018) 'Diagnosis and Management of Asthma - The Swiss Guidelines', Respiration, 95(5), pp. 364–380. doi:10.1159/000486797. DOI: https://doi.org/10.1159/000486797
Syfridiana, R. and Herawati, F. (2021) 'Roflumilast: Review of Phosphodiesterase-4 Inhibitor as Asthma Therapy', Journal of Health Science, 14(03), pp. 214–221. doi:https://doi.org/10.33086/jhs.v14i03.2114. DOI: https://doi.org/10.33086/jhs.v14i3.2114
Wenzel, S. et al. (2013) ‘Dupilumab in Persistent Asthma with Elevated Eosinophil Levels’, New England Journal of Medicine, 368(26), pp. 2455–2466. doi:10.1056/nejmoa1304048. DOI: https://doi.org/10.1056/NEJMoa1304048
Wenzel, S. et al. (2016) 'Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.', Lancet (London, England), 388(10039), pp. 31–44. doi:10.1016/S0140-6736(16)30307-5. DOI: https://doi.org/10.1016/S0140-6736(16)30307-5
Zayed, Y. et al. (2019) 'Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials', Journal of Asthma, 56(10), pp. 1110–1119. doi:10.1080/02770903.2018.1520865 DOI: https://doi.org/10.1080/02770903.2018.1520865
